Seller record · Telehealth service

Omzo

By Paul Harris, Standards EditorRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 2 of 8 criteria. S3, pharmacy identification: No filling pharmacy is named. The footer and the terms refer only to a state-licensed sterile compounding pharmacy and to certified U.S. pharmacies. 1 more criterion also fails; see the table below.

At a glance

OmzoTelehealth service

6/8criteria passed

Price: Semaglutide from $179 for the first package, then $299 at each follow-up; tirzepatide from $249 to $279 by page
Sells: compounded semaglutide, compounded tirzepatide, sexual health treatment
FDA letters: None on file

Visit Omzo See all eight dispositions

Telehealth service. Passes 6 of 8 criteria. Recorded against Standard v1.1.

A telehealth platform selling compounded semaglutide and tirzepatide through outside clinician networks, with sexual health care and other categories announced as coming soon. Care starts with an online questionnaire, and its own pages print three different starting prices for tirzepatide.

Operating entity No legal entity name appears in the footer, on the contact page, in the terms and conditions, in the privacy policy or in the HIPAA policy, which name the business only as Omzo.

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	Omzo's weight loss page; Omzo's weight loss made easy page
S2	Prescription gating	PASS	Omzo's website; Omzo's weight loss page; Omzo's terms and conditions
S3	Pharmacy identification	FAIL	Omzo's weight loss page; Omzo's terms and conditions
S4	Compounding disclosure	PASS	Omzo's weight loss page; Omzo's terms and conditions
S5	Analytical documentation	FAIL	Omzo's weight loss page; Omzo's safety information page; Omzo's terms and conditions
S6	Business address	PASS	Omzo's contact page; Omzo's terms and conditions
S7	Price disclosure	PASS	Omzo's weight loss page; Omzo's weight loss made easy page; Omzo's terms and conditions
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSClinical services come from third-party networks of U.S.-licensed clinicians who decide whether to prescribe, and the weight loss landing page names three partner doctors.Source: Omzo's weight loss page; Omzo's weight loss made easy page.

S2PASSThe home and weight loss pages start with a questionnaire about health history, which licensed clinicians review before a plan is made. The terms give a full refund when a provider finds a patient medically ineligible at the first consultation.Source: Omzo's website; Omzo's weight loss page; Omzo's terms and conditions.

S3FAILNo filling pharmacy is named. The footer and the terms refer only to a state-licensed sterile compounding pharmacy and to certified U.S. pharmacies.Source: Omzo's weight loss page; Omzo's terms and conditions.

S4PASSThe footer on every page and the terms state that the compounded medications are not FDA-approved and that the FDA has not reviewed them for safety, effectiveness or quality.Source: Omzo's weight loss page; Omzo's terms and conditions.

S5FAILNo certificate of analysis or lot document is published on the weight loss pages, the safety information or the terms.Source: Omzo's weight loss page; Omzo's safety information page; Omzo's terms and conditions.

S6PASS6192 Coastal Highway, Lewes, DE 19958, printed on the contact page as the address of Omzo. The terms name no state's law beyond the state in which Omzo operates.Source: Omzo's contact page; Omzo's terms and conditions.

S7PASSCompounded semaglutide starting at $179 on the weight loss page, which the terms give as the first package, including the consultation, medication and shipping, with each follow-up package at $299. Compounded tirzepatide starting at $279 on the weight loss page and $249 on the weight loss landing page, while the terms give $259 for the first package and $399 for each follow-up. The landing page also lists Ozempic from $1,999 a month.Source: Omzo's weight loss page; Omzo's weight loss made easy page; Omzo's terms and conditions.

S8PASSNo FDA warning letter names Omzo, and no action has halted the business.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide, sexual health treatment.

Other sellers of the same products

Who sells semaglutide Who sells tirzepatide

Visit Omzo

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.